Menu
Back to User profile » Dr Andrew Briggs
Papers published by Dr Andrew Briggs:
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A
ClinicoEconomics and Outcomes Research 2019, 11:551-565
Published Date: 6 September 2019
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
Tremblay G, Dolph M, Bhor M, Said Q, Roy A, Elliott B, Briggs A
ClinicoEconomics and Outcomes Research 2018, 10:715-721
Published Date: 5 November 2018
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, Briggs A
ClinicoEconomics and Outcomes Research 2018, 10:705-713
Published Date: 1 November 2018
Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources
Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, Risebrough NA, Slejko JF, Rutten-van Mölken MP
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3183-3194
Published Date: 1 November 2017
Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer
Tremblay G, Livings C, Crowe L, Kapetanakis V, Briggs A
ClinicoEconomics and Outcomes Research 2016, 8:323-333
Published Date: 30 June 2016